The past studies suggested that samples of tumor patients who were reactive to PD1 immune checkpoint inhibitors usually had higher densities of CD3 + T cells, CD8 + T cells and PD-1 + T cells in both invasive margin and center of tumor [48]. This evidence concerns the gene CD8A and neoplasm.